Hairy cell leukemia (HCL) is an unusual cancer of the blood. It affects B cells, a type of white blood cell (lymphocyte).
HCL is caused by the abnormal growth of B cells. The cells look "hairy" under the microscope because they have fine projections extending from their surface.
HCL usually leads to a low number of normal blood cells.
The cause of this disease is unknown, although certain genetic changes (mutations) in the cancer cells have been found. It affects men more often than women. The average age of diagnosis is 55.
Exams and Tests
Blood tests and a bone marrow biopsy can detect hairy cells.
Treatment may not be needed for the early stages of this disease. Some patients may need an occasional blood transfusion.
If treatment is needed because of very low blood counts, chemotherapy drugs can be used.
In most cases, chemotherapy can relieve the symptoms for many years. (When the signs and symptoms go away, you are said to be in remission.)
Removing the spleen may improve blood counts, but is unlikely to cure the disease. Antibiotics can be used to treat infections. People with low blood counts will receive growth factors and, possibly, transfusions.
Most patients with hairy cell leukemia can expect to live 10 years or longer after diagnosis and treatment.
The low blood counts caused by hairy cell leukemia can lead to infections, fatigue, and excessive bleeding.
There is no known way to prevent this disease.
Leukemic reticuloendotheliosis; HCL; Leukemia - hairy cell
Hasserjian RP. Hairy cell leukemia. In: Jaffe ES, Harris NL, Vardiman JW, et al., eds.Hematopathology.
National Cancer Institute: PDQ Hairy Cell Leukemia Treatment. Bethesda, MD: National Cancer Institute. Date last modified 02/28/2014. Available at http://cancer.gov/cancertopics/pdq/treatment/hairy-cell-leukemia/HealthProfessional.Accessed May 29, 2014.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Non-Hodgkin's Lymphomas. Version 2.2014. Available at http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.Accessed May 29, 2014.
Update Date 5/29/2014
Updated by: Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.